Happify Health / Twill (DarioHealth)

Happify Health (rebranded to Twill in 2022, acquired by DarioHealth in 2024) offers configurable digital therapeutic solutions for mental health and chronic conditions. The platform's Sequences technology enables bespoke configurations of evidence-based digital therapeutics, wellbeing products, care communities, coaching, and third-party services for pharmaceutical companies, health plans, and large employers. Happify launched Ensemble, a prescription digital therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), though it has not received FDA clearance. The company has partnerships with 3 of the 5 largest US health plans, over half of the top 20 global pharmaceutical companies (including Almirall, Biogen, and Elevance Health), and 3 of the 5 largest global tech companies. The DarioHealth acquisition in 2024 created one of the most comprehensive digital offerings for chronic conditions, with projected margins above 80% by 2025. The Happify consumer app has been available direct-to-consumer for over 10 years.